Myriad Genetics (MYGN) Depreciation and Depletion (2014 - 2026)

Myriad Genetics has disclosed Depreciation and Depletion across 13 years of filings, most recently posting $4.7 million for Q1 2026.

• In Q1 2026, Depreciation and Depletion fell 7.84% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $19.1 million (down 2.05% YoY), while the FY2025 annual figure was $19.5 million, changed 0.0% from the prior year.
• Depreciation and Depletion held at $4.7 million in Q1 2026, from $4.7 million in the prior quarter.
• Over the last five years, Depreciation and Depletion for MYGN reached as high as $8.7 million in Q1 2023 and fell as low as $2.7 million in Q2 2023.
• The 5-year median for Depreciation and Depletion is $4.7 million (2025), against an average of $4.4 million.
• Annual changes were most pronounced in 2023 — Depreciation and Depletion jumped 210.71% — and 2024, when it sank 43.68%.
• A 5-year view of Depreciation and Depletion shows it stood at $3.1 million in 2022, then surged by 38.71% to $4.3 million in 2023, then advanced by 16.28% to $5.0 million in 2024, then retreated by 6.0% to $4.7 million in 2025, then changed by 0.0% to $4.7 million in 2026.
• According to Business Quant data, Depreciation and Depletion over the past three periods registered $4.7 million, $4.7 million, and $4.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.